Synchron’s foundational technology, a motor neuroprosthesis, or motor BCI, is implanted via the jugular vein using neurointerventional techniques commonly used to treat stroke, and does not require ...

NEW YORK--(BUSINESS WIRE)--Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ ...

Synchron has cemented its position as the frontrunner in brain computer interface (BCI) clinical trials, after the company reported positive 12-month safety and efficacy data for its Stentrode device.

Even though brain-computer interfaces (BCIs) are still an emerging part of neurotechnology, Neuralink, Elon Musk's BCI startup, has dominated headlines about the space. But rival company Synchron is ...

US-based Synchron has secured $200m in a Series D funding round to drive the commercial rollout of its Stentrode brain-computer interface (BCI) platform and aid in the creation of next-generation ...